Soft tissue and bone penetration abilities of daptomycin in diabetic patients with bacterial foot infections

Safety and Efficacy of Daptomycin in the Treatment of Osteomyelitis: Results from the CORE®Registry

(2014) J.A. Crompton et al.   JOURNAL OF CHEMOTHERAPY

Safety and Clinical Outcomes when Utilizing High-Dose (≥8 mg/kg) Daptomycin Therapy

(2009) Pamela A Moise et al.   ANNALS OF PHARMACOTHERAPY

Efficacy of High Doses of Daptomycin versus Alternative Therapies against Experimental Foreign-Body Infection by Methicillin-Resistant Staphylococcus aureus

(2009) O. Murillo et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Antimicrobial susceptibility of Gram-positive bacteria isolated from US medical centers: results of the Daptomycin Surveillance Program (2007–2008)

(2009) Helio S. Sader et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Characterisation of a Staphylococcus aureus strain with progressive loss of susceptibility to vancomycin and daptomycin during therapy

(2009) Fred C. Tenover et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

High fosfomycin concentrations in bone and peripheral soft tissue in diabetic patients presenting with bacterial foot infection

(2009) M. V. Schintler et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

In Vivo Microdialysis Study of the Penetration of Daptomycin into Soft Tissues in Diabetic versus Healthy Volunteers

(2008) A. Kim et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacokinetics of linezolid in bone tissue investigated by in vivo microdialysis

(2007) Lars B. Stolle et al.   SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES